Geoffrey L. Uy

14.2k citations

214 papers · 4.6k indexed · h-index 32

Hematology top 0.2%
Molecular Biology top 5%
Oncology top 2%
Immunology top 5%
Public Health, Environmental and Occupational Health top 2%

Co-authors: John F. DiPersio Michael P. Rettig Peter Westervelt Ravi Vij Keith Stockerl‐Goldstein Camille N. Abboud Amanda F. Cashen Julie Ritchey
Topics: Acute Myeloid Leukemia Research (127 papers)Hematopoietic Stem Cell Transplantation (55 papers)Acute Lymphoblastic Leukemia research (51 papers)
Cited by: Hematology Oncology Genetics
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: United States Canada United Kingdom

In The Last Decade

Geoffrey L. Uy

202 papers receiving 4.5k citations

Peers

Countries citing papers authored by Geoffrey L. Uy

Since Specialization

Citations

This map shows the geographic impact of Geoffrey L. Uy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey L. Uy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey L. Uy more than expected).

Fields of papers citing papers by Geoffrey L. Uy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey L. Uy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey L. Uy. The network helps show where Geoffrey L. Uy may publish in the future.

Co-authorship network of co-authors of Geoffrey L. Uy

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey L. Uy. A scholar is included among the top collaborators of Geoffrey L. Uy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey L. Uy. Geoffrey L. Uy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies 2025 ·Leukemia ·(unknown),Deedra Nicolet,(unknown),Daelynn R. Buelow,Shelley Orwick,Charles T. Gregory,(unknown),(unknown),Jonathan E. Kolitz,Bayard L. Powell,William Blum,Maria R. Baer,John C. Byrd,Wendy Stock,Geoffrey L. Uy,Krzysztof Mrózek,Ann‐Kathrin Eisfeld,Xiaolin Cheng,Sharyn D. Baker,James S. Blachly	1
2	CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis 2025 ·Cardio-Oncology ·Joshua D. Mitchell,Michael Pfeiffer,John Boehmer,John Gorcsan,(unknown),Yoshiyuki Orihara,(unknown),(unknown),Stefan Faderl,Tara L. Lin,Geoffrey L. Uy,Jeffrey E. Lancet,Jörge E. Cortes	0
3	A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02 2024 ·Blood ·Jessica K. Altman,Zhuoxin Sun,Alexander E. Perl,Richard F. Little,Steven D. Gore,Laura C. Michaelis,Geoffrey L. Uy,Yasmin Abaza,Sameem Abedin,John L. Reagan,Ehab Atallah,Selina M. Luger,Mark R. Litzow	3
4	Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients 2024 ·Blood ·(unknown),(unknown),Peter Y. Zhao,Ningying Wu,Feng Gao,Geoffrey L. Uy,John F. DiPersio,Zachary Crees	0
5	Association of social deprivation with survival in younger adult patients with AML: an Alliance study 2023 ·Blood Advances ·(unknown),Jessica Kohlschmidt,Krzysztof Mrózek,Deedra Nicolet,Alice S. Mims,James S. Blachly,Shelley Orwick,Karilyn Larkin,Christopher C. Oakes,Andrew Hantel,Andrew J. Carroll,William Blum,Bayard L. Powell,Geoffrey L. Uy,Richard M. Stone,Richard A. Larson,John C. Byrd,Electra D. Paskett,Jesse J. Plascak,Ann‐Kathrin Eisfeld	5
6	Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 2023 ·Blood ·(unknown),Zachary Crees,Michael Slade,Mark A. Schroeder,Ravi Vij,Geoffrey L. Uy,Keith Stockerl‐Goldstein	1
7	Clonal hematopoiesis in survivors of childhood cancer 2023 ·Blood Advances ·Danielle Novetsky Friedman,(unknown),Chaya S. Moskowitz,(unknown),Kimberly L. Turner,Jie Liu,Nancy Bouvier,Michael F. Walsh,Barbara Spitzer,Andrew L. Kung,Michael F. Berger,Megan A. Cooper,Iskra Pusic,Geoffrey L. Uy,Daniel C. Link,Todd E. Druley,Luis A. Díaz,Ross L. Levine,Neerav Shukla,Kelly L. Bolton	13
8	Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation 2023 ·Transplantation and Cellular Therapy ·(unknown),Jaebok Choi,Matthew Cooper,(unknown),Mark A. Fiala,Jingxia Liu,Iskra Pusic,Rizwan Romee,Amanda F. Cashen,Meagan A. Jacoby,Keith Stockerl‐Goldstein,Camille N. Abboud,Ravi Vij,Geoffrey L. Uy,Peter Westervelt,Matthew J. Walter,John F. DiPersio,Mark A. Schroeder	2
9	Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study 2023 ·Leukemia ·Krzysztof Mrózek,Jessica Kohlschmidt,James S. Blachly,Deedra Nicolet,Andrew J. Carroll,Kellie J. Archer,Alice S. Mims,Karilyn Larkin,Shelley Orwick,Christopher C. Oakes,Jonathan E. Kolitz,Bayard L. Powell,William Blum,Guido Marcucci,Maria R. Baer,Geoffrey L. Uy,Wendy Stock,John C. Byrd,Ann‐Kathrin Eisfeld	31
10	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud,Feng Gao,Michael P. Rettig,(unknown),Leah Gehrs,Nicholas A. Wallace,Camille N. Abboud,Peter Westervelt,Geoffrey L. Uy,Amanda F. Cashen,Matthew Christopher,Armin Ghobadi,Meagan A. Jacoby,Iskra Pusic,Keith Stockerl-Goldstein,John F. DiPersio,Mark A. Schroeder	1
11	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease 2021 ·Blood ·Iskra Pusic,Tanner M. Johanns,Stefanie Sarantopoulos,(unknown),(unknown),Peter Westervelt,Amanda F. Cashen,Geoffrey L. Uy,Camille N. Abboud,John F. DiPersio	1
12	A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome 2021 ·Blood ·Meagan A. Jacoby,David A. Sallman,Bart L. Scott,(unknown),Fei Wan,John F. DiPersio,Ramzi Abboud,Keith Stockerl‐Goldstein,Rami S. Komrokji,Mark A. Schroeder,Matthew J. Walter,Peter Westervelt,Geoffrey L. Uy	6
13	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) 2019 ·Blood ·R. Coleman Lindsley,Christopher J. Gibson,H. Moses Murdock,Richard M. Stone,Jörge E. Cortes,Geoffrey L. Uy,Tara L. Lin,Ellen K. Ritchie,Thomas Prébet,Robert J. Ryan,Stefan Faderl,Jeffrey E. Lancet	27
14	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study 2019 ·Blood ·Geoffrey L. Uy,Mark D. Minden,Pau Montesinos,Daniel J. DeAngelo,Jessica K. Altman,(unknown),Paresh Vyas,Yngvar Fløisand,María‐Belén Vídriales,Bjørn Tore Gjertsen,Jordi Esteve,Tonia J. Buchholz,Suzana S. Couto,Jinhong Fan,Bishoy Hanna,Li Li,Daniel W. Pierce,Kristen Hege,Michael Pourdehnad,Amer M. Zeidan	23
15	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product 2018 ·Blood ·Michael P. Rettig,Geoffrey L. Uy,Asad Bashey,Steven M. Devine,Samantha Jaglowski,(unknown),Ella Sorani,(unknown),Osnat Bohana‐Kashtan,Stephen Shaw,Peter Westervelt,John F. DiPersio	1
16	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen 2017 ·Cancer Medicine ·Alaa M. Ali,(unknown),Feng Gao,Geoffrey L. Uy,Amanda F. Cashen,Meagan A. Jacoby,Lukas D. Wartman,Armin Ghobadi,Iskra Pusic,Rizwan Romee,Todd A. Fehniger,Keith Stockerl‐Goldstein,Ravi Vij,Stephen T. Oh,Camille N. Abboud,Mark A. Schroeder,Peter Westervelt,John F. DiPersio,John S. Welch	21
17	A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS 2017 ·Blood ·(unknown),Amanda F. Cashen,John F. DiPersio,Meagan A. Jacoby,Iskra Pusic,Rizwan Romee,Geoffrey L. Uy,Peter Westervelt	3
18	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60 2015 ·Blood ·Farhad Ravandi,Megan Othus,Susan O’Brien,Stephen J. Forman,Chul S. Ha,Jeffrey Y.C. Wong,Martin S. Tallman,Elisabeth Paietta,Janis Racevskis,Geoffrey L. Uy,Uma Borate,Partow Kebriaei,Laura Kingsbury,Hagop M. Kantarjian,Jerald P. Radich,Harry P. Erba,Frederick R. Appelbaum	11
19	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia 2012 ·Blood ·Geoffrey L. Uy,Michael P. Rettig,Ibraheem Motabi,Kyle McFarland,Kathryn Trinkaus,Lindsay Hladnik,Shashikant Kulkarni,Camille N. Abboud,Amanda F. Cashen,Keith Stockerl‐Goldstein,Ravi Vij,Peter Westervelt,John F. DiPersio	310
20	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia 2010 ·Blood ·Todd A. Fehniger,Geoffrey L. Uy,Kathryn Trinkaus,(unknown),(unknown),Camille N. Abboud,Amanda F. Cashen,Keith Stockerl‐Goldstein,Peter Westervelt,John F. DiPersio,Ravi Vij	82

About Geoffrey L. Uy

Geoffrey L. Uy is a scholar working on Hematology, Genetics and Oncology, having authored 214 papers that have together received 4.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (127 papers), Hematopoietic Stem Cell Transplantation (55 papers) and Acute Lymphoblastic Leukemia research (51 papers). The work is most often cited by research in Hematology (2.9k citations), Oncology (1.5k citations) and Genetics (536 citations). Geoffrey L. Uy has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John F. DiPersio, Michael P. Rettig, Peter Westervelt, Ravi Vij, Keith Stockerl‐Goldstein, Camille N. Abboud, Amanda F. Cashen, Amanda F. Cashen, Julie Ritchey and Matthew Holt. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact